Newron Presents 2024 Financial Results and Provides 2025 Outlook

About this update from Newron Pharmaceuticals S.p.a.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":281,"url":"https://media.zenfs.com/en/business-wire.com/4a181ed32bafc6c73cd6454bba2f4b2c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/i78xf2XOrt9g2u32ondNog--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4a181ed32bafc6c73cd6454bba2f4b2c","width":480,"height":281}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p","attribs":{}},{"type":"text","content":"MILAN, April 01, 2025--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2024, and provided an outlook for 2025.","length":408,"tagName":"p"},{"type":"text","content":"Highlights 2024:","length":16,"tagName":"p"},{"type":"text","content":"Evenamide","length":9,"tagName":"p"},{"type":"text","content":"Exceptional data from study 014/015 and study 008A:","length":51,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Demonstrated significant and increasing efficacy of evenamide as an add-on therapy on multiple measures of psychopathology in treatment-resistant schizophrenia (TRS) and chronic schizophrenia","length":191,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Confirmed evenamide’s favorable safety and tolerability profile","length":63,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The data adds to the growing evidence that evenamide’s glutamatergic inhibition mechanism of action offers an innovative therapeutic option to schizophrenia patients who are not benefiting from current antipsychotic treatments on the market","length":240,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":494,"olType":false},{"type":"text","content":"Strategic licensing and partnerships:","length":37,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In December 2024, the Company announced a licensing agreement with EA Pharma, a subsidiary of Eisai, to dev...

More updates from Newron Pharmaceuticals S.p.a.